NCT07664046 The Effectiveness of the Self-Assembling Peptide P11-4 in the Remineralization of Enamel Carious White Spot Lesions
| NCT ID | NCT07664046 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Warsaw |
| Condition | White Spot Lesions on Smooth Surface of Tooth |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2026-02-02 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is three-arm Randomized Controlled Trial. The main goal is to evaluate the effectiveness of self-assembling peptide P11-4 (SAP P11-4) in the remineralization of enamel carious white spot lesions. Participants with carious white spot lesions will be assigned to one of three study groups and remineralisation agents will be applied according to the study protocol. The primary objective is to assess changes in the carious white spot lesions over time using quantitative light-induced fluorescence and clinical evaluation.
Eligibility Criteria
Inclusion Criteria: 1. Age \>10 years and \<18 years. 2. Presence of at least 2 active enamel carious white spot lesions on a smooth tooth surface (labial/buccal surfaces of permanent teeth) based on International Caries Detection (ICDAS II) and Assessment System -Lesion Activity Assessment (ICDAS-LAA), and Lesion Activity Assessment (LAA criteria). 3. Tooth eligible for treatment: 1. Vital pulp, 2. no loss of hard dental tissues within the investigated lesion (ICDAS II) code 1 or 2 , LAA code 1, ICDAS-LAA\>7; 3. QLF score parameters consistent with demineralization without loss of tissue continuity- code 1 or 2), 4. no history of trauma to the tooth. 4. Systemically healthy patient. 5. No contraindications to the use of fluoride preparations. 6. No fixed orthodontic appliance. 7. Written consent for participation in the study signed by the legal guardian, or by the legal guardian and the patient. Exclusion Criteria: 1. Systemic diseases or chronic medication use due to chronic conditions. 2. Viral/bacterial illness on the day of the visit, e.g., herpetic stomatitis, influenza, tonsillitis (temporary restriction). 3. Pregnancy or breastfeeding. 4. Allergy to any component of the SAP P11-4 preparation or the fluoride varnish. 5. Professional fluoride prophylaxis performed \<3 months ago. 6. Presence of cavitation (loss of hard tissues) in the treated tooth - ICDAS II code ≥3, ICDAS-LAA\<7, LAA code 0, 2-9. 7. Carious WSL previously treated with the Icon resin infiltrant (methacrylate resin). 8. Developmental enamel defects. 9. Patient undergoing orthodontic treatment with fixed appliances. 10. Inability to ensure regular follow-up visits. 11. Lack of cooperation from the guardian or the patient. 12. Refusal to participate in the study and/or absence of written consent.
Contact & Investigator
Dorota Olczak-Kowalczyk, Prof.
PRINCIPAL INVESTIGATOR
Medical University of Warsaw
Frequently Asked Questions
Who can join the NCT07664046 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying White Spot Lesions on Smooth Surface of Tooth. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07664046 currently recruiting?
Yes, NCT07664046 is actively recruiting participants. Contact the research team at pedodoncja@wum.edu.pl for enrollment information.
Where is the NCT07664046 trial being conducted?
This trial is being conducted at Warsaw, Poland.
Who is sponsoring the NCT07664046 clinical trial?
NCT07664046 is sponsored by Medical University of Warsaw. The principal investigator is Dorota Olczak-Kowalczyk, Prof. at Medical University of Warsaw. The trial plans to enroll 75 participants.